Quantitative determination of lobeglitazone sulfate and glimepiride in combined tablet by robust high‐performance thin layer chromatographic method

• Published in: Separation science plus 2024-07, Vol.7 (7), p.n/a
• Main Authors: Sen, Ashim Kumar, Sarkar, Tantul, Sen, Dhanya B., Maheshwari, Rajesh A., Zanwar, Aarti S., Dumpala, Rajesh L.
• Format: Article
• Language: English
• Subjects: anti‐diabetic agent; glimepiride; high‐performance thin‐layer chromatography; lobeglitazone sulfate; tablet formulation
• ISSN: 2573-1815; 2573-1815
• DOI: 10.1002/sscp.202400059

A combination of fixed dose tablet containing 0.5 mg lobeglitazone sulfate (LBZ) and 1 mg glimepiride (GLM) has demonstrated efficacy in enhancing glycemic control in diabetes. The projected work aimed to develop and validate a high‐performance thin‐layer chromatographic (HPTLC) methodology for the precise quantification of both the drugs in tablet formulations. The HPTLC analysis utilized aluminium plates layered with silica gel 60F254, and the solvent system consisted of ethyl acetate, benzene, and hexane (4:3:1 v/v/v) followed by densitometric scanning at 238 nm. The Rf value was found to be 0.68 ± 0.001 for LBZ and 0.48 ± 0.002 for GLM. The methodology exhibited linearity in the range of 100–2000 ng/band for LBZ and 200–4000 ng/band for GLM, with correlation coefficients of 0.9988 and 0.9981, respectively. Exceptional sensitivity was observed, with detection limits of 23.86 ng/band for LBZ and 58.26 ng/band for GLM, along with quantification limits of 72.32 ng/band for LBZ and 176.55 ng/band for GLM. The method demonstrated precision (% relative standard deviation of peak area